US Cost Burden of Relapsed Refractory Multiple Myeloma during Third and Later Lines of Treatment
US Cost Burden of Relapsed Refractory Multiple Myeloma during Third and Later Lines of Treatment is a paper indexed in ScholarIQ from OpenAlex.
How many citations does US Cost Burden of Relapsed Refractory Multiple Myeloma during Third and Later Lines of Treatment have?
US Cost Burden of Relapsed Refractory Multiple Myeloma during Third and Later Lines of Treatment has 6 citations in the OpenAlex counts ScholarIQ stores.
When was US Cost Burden of Relapsed Refractory Multiple Myeloma during Third and Later Lines of Treatment published?
US Cost Burden of Relapsed Refractory Multiple Myeloma during Third and Later Lines of Treatment has 2019 year in the ScholarIQ index.
What is the open-access status of US Cost Burden of Relapsed Refractory Multiple Myeloma during Third and Later Lines of Treatment?
US Cost Burden of Relapsed Refractory Multiple Myeloma during Third and Later Lines of Treatment has closed oa status in the ScholarIQ index.
What is the DOI of US Cost Burden of Relapsed Refractory Multiple Myeloma during Third and Later Lines of Treatment?
The DOI for US Cost Burden of Relapsed Refractory Multiple Myeloma during Third and Later Lines of Treatment is on the source record.
What is the OpenAlex record for US Cost Burden of Relapsed Refractory Multiple Myeloma during Third and Later Lines of Treatment?
The OpenAlex for US Cost Burden of Relapsed Refractory Multiple Myeloma during Third and Later Lines of Treatment is on the source record.